Pioneering MedTech company, Tachmed, has moved into Leap – a new landmark lab incubator space at ARC West London – to drive the next phase of its development strategy.
Co-founded by Paul Christie and Lord Maxwell Beaverbrook in 2018, Tachmed is reimagining the world of diagnostics through the development of a low-cost, AI-powered device, TachShield, which will enable users to self-test for a range of conditions — anytime, anywhere.
Set to officially launch to market in 2026, TachShield will quickly identify a range of conditions, from chronic illnesses such as cardiovascular disease, obesity, and other inflammatory disease biomarkers to infectious diseases such as dengue, flu, COVID-19, and other viruses.
Located in West London near Hammersmith, ARC West London is part of the ARC Group, Europe’s leading network of science and innovation clusters at the forefront of major knowledge economies such as Oxford and London.
Having officially opened its doors in October 2025, Leap is already home to five early-stage science companies, filling 5 of the 25 available benches. A fundamental part of ARC West London, Leap provides the space and support for scientists and innovators to turn early-stage ideas into commercialised products by scaling them under one roof.
In moving into the impressive space, the Tachmed team now plan to finalise the development of TachShield ahead of its scheduled launch in 2026.
Paul Christie, CEO of Tachmed, confirmed: “Moving into Leap marks a major milestone for Tachmed as we accelerate the final phase of development for TachShield. ARC West London provides the ideal environment for innovation, collaboration and scale, and being surrounded by world-class innovators and leading clinical and academic institutions will be invaluable as we move towards delivering a new standard of accessible, AI-enhanced diagnostics.”
Underpinned by a team of specialists, Tachmed’s advanced smart health platform will have the capability to significantly reduce healthcare waiting lists, while saving vital costs, resource and even lives through early diagnosis.
ARC West London provides the space and support for scientists and innovators to turn early-stage ideas into commercialised products by scaling under one roof. The campus is already home to leading science organisations including Kesmalea, Sania Therapeutics and Epsilogen and sits minutes from Imperial’s White City and Hammersmith Hospital Campuses and the Imperial College Healthcare NHS Trust’s Charing Cross Hospital.